Action of 2,3-butanedione monoxime on calcium signals in frog cut twitch fibres containing antipyrylazo III.
1. The effects of 2,3-butanedione monoxime (BDM) on the optical retardation and myoplasmic Ca2+ signal were studied in twitch fibres of Rana temporaria. The myoplasmic Ca2+ transient in response to action potential stimulation was monitored in cut fibres containing Antipyrylazo III under current clamp in a double Vaseline-gap chamber. 2. In fibres not stretched adequately to suppress all the contraction, BDM blocked the movement-related intrinsic optical signal at 810 nm very effectively. 3. In fibres stretched to sarcomere lengths greater than or equal to 4 microns to reduce the contraction to below detectable levels, the effect of BDM on the Ca(2+)-Antipyrylazo III signal was studied after correcting for the instrinsic signal unrelated to movement. With increasing concentrations of BDM, the peak of the Ca(2+)-Antipyrylazo III signal was suppressed progressively. Concomitantly, the half-width was prolonged somewhat. On average, 5, 10 and 20 mM-BDM reduced the peak amplitude to 88, 78 and 54% of control, respectively. 4. BDM had no effect on the rising phase or the peak amplitude of the retardation signal measured at 720 nm, but suppressed the undershoot in the decay phase of the signal in a dose-dependent manner. BDM also had no effect on the late pedestal level of the signal. 5. During repetitive stimulation by a train of ten action potentials, 10 mM-BDM suppressed the second to the tenth peaks of the Ca2+ signal and of the retardation signal more effectively than the first peak. Twenty millimolar BDM almost completely suppressed the later peaks of both signals such that the signals decayed with a time course similar to that elicited by a single action potential. 6. The effect of BDM on the Ca(2+)-Antipyrylazo III signal was also studied in fibres under voltage clamp; 10 mM-BDM lowered the threshold for the Ca(2+)-Antipyrylazo III transient by a few millivolts and reduced the steepness of the peak amplitude versus voltage plot near threshold. 7. Based on a model used by Baylor, Chandler & Marshall (1983) to estimate the net Ca2+ release from the sarcoplasmic reticulum, 10 and 20 mM-BDM were found to reduce the peak release to 75 and 52%, to prolong the half-width of the release waveform to 118 and 147%, and to reduce the peak uptake to 76 and 54% of control values, respectively. 8. It is concluded that BDM affects the optical retardation and myoplasmic Ca2+ signal monitored with Antipyrylazo III in a dose-dependent manner.(ABSTRACT TRUNCATED AT 400 WORDS)
Maylie
J
J
Department of Obstetrics and Gynecology, Oregon Health Science University, Portland 97201.
Hui
C S
CS
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002801:Cholinesterase Reactivators / Q000494:pharmacology*; D003931:Diacetyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D009119:Muscle Contraction / Q000187:drug effects; D009282:Naphthalenesulfonates / Q000378:metabolism; D010812:Physical Stimulation; D011896:Rana temporaria; D012519:Sarcoplasmic Reticulum / Q000378:metabolism
D002801:Cholinesterase Reactivators; D009282:Naphthalenesulfonates; C004717:diacetylmonoxime; C016238:antipyrylazo III; D003931:Diacetyl; D002118:Calcium